In this episode of Denatured, you'll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, ...
EADaily, February 19th, 2026. Singer Lyubov Uspenskaya has not celebrated her birthday and other holidays for four years. She told Channel Five about this.
The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics' first patient dosing in ...
AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the first participant has been dosed in its ...
A male teenage pupil opened fire inside a secondary school in the latest school attack to shake Vladimir Putin's country. However, regional officials later confirmed that no one sustained ...
The ancient town of Uglich (155 miles north of Moscow) was founded in the 10th century. With its beautiful location on the Volga River, Uglich is one of the most important tourist destinations in ...
VTx-002 is a first-in-class vectorized antibody to holistically target TDP-43 pathology in ALS recently granted FDA Fast Track Designation for expedited review Amsterdam, The Netherlands, and Boston, ...
Russian opera singer Anna Netrebko has submitted documents to terminate the activities of an individual entrepreneur in the Russian Federation, which were reviewed by Izvestia on February 1. It is ...
Based on physico-chemical studies of water-salt systems formed by ammonium and potassium nitrates and sulfates, the formulation of a new fertilizer has been developed by the staff of the Laboratory of ...
VectorY Therapeutics has dosed the first participant in its Phase I/II PIONEER-ALS clinical trial, which is investigating VTx-002, a vectorised antibody targeting TDP-43 pathology, in individuals with ...
Be the first to get news, photos, videos & more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results